Dr. Reddy's Laboratories/$RDY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Dr. Reddy's Laboratories

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Ticker

$RDY
Sector

Primary listing

NYSE

Employees

27,811

Headquarters

Hyderabad, India

RDY Metrics

BasicAdvanced
$12B
18.37
$0.77
0.38
$0.07
0.50%

What the Analysts think about RDY

Analyst ratings (Buy, Hold, Sell) for Dr. Reddy's Laboratories stock.

Bulls say / Bears say

Dr. Reddy’s aims to roll out a generic version of semaglutide (Wegovy) in 87 countries starting next year, setting the stage to tap into the booming $150 billion obesity drug market by the early 2030s.
The company’s Q2 revenue from Europe more than doubled, bolstered by robust demand for nicotine replacement therapy products acquired from Haleon in 2024, highlighting successful expansion beyond traditional generics.
Management expects Indian generic drug makers, including Dr. Reddy’s, to stay competitive in spite of proposed U.S. tariffs, citing low-cost manufacturing and geographic flexibility that help protect margins across key markets.
Dr. Reddy’s Q2 net profit of ₹14.18 billion was just below analysts’ expectation of ₹14.94 billion, reflecting ongoing pricing pressures and intense competition that reduced overall earnings.
North America sales dropped 11.3% in the June quarter as price erosion affected key products including generic Lenalidomide, and additional revenue pressure is likely once Revlimid’s patent expiry in 2026 leads to more competition.
Novo Nordisk has sued Dr. Reddy’s for patent infringement over its planned generic semaglutide, exposing the company to legal risks that could delay launch and add costs.
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.

RDY Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RDY Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RDY

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs